Androgen deprivation prior to radical prostatectomy for T2b and T3 prostate cancer
- PMID: 7509535
- DOI: 10.1016/0090-4295(94)90219-4
Androgen deprivation prior to radical prostatectomy for T2b and T3 prostate cancer
Abstract
Objective: In an effort to improve on the results of radical prostatectomy for clinical stages T2b and T3 prostate cancer, a selected group of patients received androgen deprivation for three to sixteen months prior to surgery.
Methods: Fifteen men with clinical T2b and 22 with small T3 tumors received a luteinizing hormone-releasing hormone analog (n = 34) or a bilateral orchiectomy (n = 3) three to sixteen months prior to radical retropubic prostatectomy. The prostate was evaluated with particular attention to tumor grade, presence of extracapsular extension, tumor at the inked margin, seminal vesicle invasion, and tumor in the lymph nodes.
Results: No patient had clinical or chemical (prostate-specific antigen [PSA]) progression during androgen deprivation. The PSA level declined a mean 90 percent and remained above 4 ng/mL in only two patients. The prostate volume decreased an estimated 30-50 percent. Prostate cancer at the inked margin was found in 15 (41%) and seminal vesicle involvement in 11 (30%) patients. Five (14%) had tumor in regional lymph nodes. There was no difference in regard to positive margins or lymph node metastases between those clinically staged as T2b and those preoperatively staged as T3. Fourteen patients have received adjuvant therapy (13 androgen deprivation, one radiation therapy). None has progressed (mean follow-up, 38.4 months). Of 23 who did not receive immediate additional therapy, six (26%) had progression, as was evident from an increase in PSA and have since been treated. Only one continued to progress. Thirty-five of the 37 patients are alive. Seventeen (46%) are tumor free (PSA < 0.4 ng/mL) without further androgen deprivation.
Conclusions: Only a prospective randomized trial can determine whether androgen deprivation prior to radical prostatectomy has a role. The results from this trial are encouraging for several reasons. The prostate is much smaller as a result of androgen deprivation and this may facilitate surgery. Although the great majority of these patients were expected to be margin positive, 60 percent had negative margins and only 14 percent had positive lymph nodes.
Similar articles
-
Significance of androgen deprivation prior to radical prostatectomy, with special reference to prostate-specific antigen.World J Urol. 1993;11(4):221-6. doi: 10.1007/BF00185074. World J Urol. 1993. PMID: 7508788 Clinical Trial.
-
Induction androgen deprivation therapy before radical prostatectomy for prostate cancer--initial results.Br J Urol. 1996 Mar;77(3):423-8. doi: 10.1046/j.1464-410x.1996.85118.x. Br J Urol. 1996. PMID: 8814850
-
High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer.Br J Urol. 1995 Jun;75(6):771-7. doi: 10.1111/j.1464-410x.1995.tb07389.x. Br J Urol. 1995. PMID: 7542137 Clinical Trial.
-
The role of induction androgen deprivation prior to radical prostatectomy.Eur Urol. 1996;29 Suppl 2:114-8. doi: 10.1159/000473850. Eur Urol. 1996. PMID: 8717473 Review.
-
Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer.J Urol. 1998 Aug;160(2):299-315. J Urol. 1998. PMID: 9679867 Review.
Cited by
-
Neo-adjuvant hormonal therapy of prostate cancer.Urol Res. 1997;25 Suppl 2:S57-62. doi: 10.1007/BF00941989. Urol Res. 1997. PMID: 9144888
-
Surgery for locally advanced disease.Curr Urol Rep. 2006 May;7(3):209-16. doi: 10.1007/s11934-006-0023-z. Curr Urol Rep. 2006. PMID: 16630524 Review.
-
The addition of chemotherapy in the definitive management of high risk prostate cancer.Urol Oncol. 2018 Nov;36(11):475-487. doi: 10.1016/j.urolonc.2018.07.020. Epub 2018 Oct 9. Urol Oncol. 2018. PMID: 30309766 Free PMC article. Review.
-
Inflection points in urology as witnessed by Mark Soloway Part 2: Prostate and kidney cancers.Cent European J Urol. 2023;76(4):283-286. doi: 10.5173/ceju.2023.3E. Epub 2023 Nov 25. Cent European J Urol. 2023. PMID: 38230321 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous